Natural history of acute and chronic hepatitis C

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 401-412

  Maasoumy, Benjamin ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute hepatitis; Antiviral therapy; Chronic hepatitis; Cirrhosis; HCC; Hepatitis C; Natural history

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; BILIRUBIN; HEPATITIS C ANTIBODY; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ACUTE HEPATITIS C; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANEMIA; ANTIBODY DETECTION; ANTIVIRAL THERAPY; BILIRUBIN BLOOD LEVEL; CANCER RISK; CAUSE OF DEATH; CELLULAR IMMUNITY; CLINICAL FEATURE; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DISEASE COURSE; ENVIRONMENTAL FACTOR; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTION RISK; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER FIBROSIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SERODIAGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS CARCINOGENESIS; VIRUS TRANSMISSION;

EID: 84870410922     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.009     Document Type: Article

References (111)

1. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infec 17 2 2011 Feb 107 115
2. EASL EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2 2011 Aug 245 264
3. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guideline by the american association for the study of liver diseases Hepatology 54 4 2011 Oct 1433 1444
4. B. Veldt, E. Heathcote, H. Wedemeyer, J. Reichen, W. Hofmann, and S. Zeuzem Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 10 2007 Nov 20 677 684
5. A.C. Cardoso, R. Moucari, C. Figueiredo-Mendes, M.P. Ripault, N. Giuily, and C. Castelnau Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis J Hepatol 52 5 2010 May 652 657
6. J. Grebely, M. Prins, M. Hellard, A.L. Cox, W.O. Osburn, and G. Lauer Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine Lancet Infec Dis 12 5 2012 May 408 414
7. M. Lopez-Dieguez, M.L. Montes, J.F. Pascual-Pareja, C. Quereda, M.A. Von Wichmann, and J. Berenguer The natural history of liver cirrhosis in HIVhepatitis C virus-coinfected patients Aids 25 7 2011 Apr 24 899 904
8. J. Mosley, E. Operskalski, L. Tobler, W. Andrews, B. Phelps, and J. Dockter Viral and host factors in early hepatitis C virus infection Hepatology 42 1 2005 Jul 86 92
9. J. Hoofnagle Hepatitis C: the clinical spectrum of disease Hepatology 26 31 1997 Sep 15S 20S
10. P. Farci, H. Alter, D. Wong, R. Miller, J. Shih, and B. Jett A long-term study of hepatitis C virus replication in non-A, non-B hepatitis N Engl J Med 325 2 1991 Jul 11 98 104
11. A. Bertoletti, and C. Ferrari Kinetics of the immune response during HBV and HCV infection Hepatology 38 1 2003 Jul 4 13
12. A. Cox, D. Netski, T. Mosbruger, S. Sherman, S. Strathdee, and D. Ompad Prospective evaluation of community-acquired acute-phase hepatitis C virus infection Clin Infect Dis 40 7 2005 Apr 1 951 958
13. K. Deterding, J. Wiegand, N. Gruner, A. Hahn, E. Jackel, and M. Jung The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection Z Gastroenterol 47 6 2009 Jun 531 540
14. J. Orland, T. Wright, and S. Cooper Acute hepatitis C Hepatology 33 2 2001 Feb 321 327
15. R. Loomba, M. Rivera, R. McBurney, Y. Park, V. Haynes-Williams, and B. Rehermann The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes Aliment Pharmacol Ther 33 5 2011 Mar 559 565
16. M. Vogel, K. Deterding, J. Wiegand, N.H. Gruner, A. Baumgarten, and M.C. Jung Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection Clin Infec Dis 49 2 2009 Jul 15 317 319
17. J. Wiegand, P. Buggisch, W. Boecher, S. Zeuzem, C. Gelbmann, and T. Berg Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection:The HEP-NET acute-HCV-II study Hepatology 43 2 2006 Feb 250 256
18. A. Takaki, M. Wiese, G. Maertens, E. Depla, U. Seifert, and A. Liebetrau Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature Medicine 6 5 2000 May 578 582
19. T. Santantonio, J. Wiegand, and J.T. Gerlach Acute hepatitis C: current status and remaining challenges Journal of Hepatology 49 4 2008 625 633
20. J. Wiegand, K. Deterding, M. Cornberg, and H. Wedemeyer Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha J Antimicrob Chemother 62 5 2008 860 865
21. L. Seeff, and J. Hoofnagle National institutes of health consensus development conference: management of hepatitis C: 2002 Hepatology 36 5 Suppl. 1 2002 Nov S1 S2
22. I. Bakr, C. Rekacewicz, M. El Hosseiny, S. Ismail, M. El Daly, and S. El-Kafrawy Higher clearance of hepatitis C virus infection in females compared with males Gut 55 8 2006 Aug 1183 1187
23. H. Rao, D. Sun, D. Jiang, R. Yang, F. Guo, and J. Wang IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection J Viral Hepat 19 3 2012 Mar 173 181
24. E. Villa, A. Karampatou, C. Camma, A. Di Leo, M. Luongo, and A. Ferrari Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C Gastroenterology 140 3 2011 Mar 818 829
25. J. Hayashi, Y. Kishihara, K. Ueno, K. Yamaji, Y. Kawakami, and N. Furusyo Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection Arch Intern Med 158 2 1998 Jan 26 177 181
26. M. Vogt, T. Lang, G. Frosner, C. Klingler, A. Sendl, and A. Zeller Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening N Engl J Med 341 12 1999 Sep 16 866 870
27. S. Rerksuppaphol, W. Hardikar, and G. Dore Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children J Gastroenterol Hepatol 19 12 2004 Dec 1357 1362
28. J. Micallef, J. Kaldor, and G. Dore Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies J Viral Hepat 13 1 2006 Jan 34 41
29. C. Wang, E. Krantz, J. Klarquist, M. Krows, L. McBride, and E. Scott Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance J Infect Dis 196 10 2007 Nov 15 1474 1482
30. B. Rehermann Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J Clin Inves 119 7 2009 Jul 1745 1754
31. G. Alter, S. Jost, S. Rihn, L.L. Reyor, B.E. Nolan, and M. Ghebremichael Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+NK cells in acute HCV infection may predict viral clearance J Hepatol 55 2 2011 Aug 278 288
32. K.A. Stegmann, N.K. Bjorkstrom, S. Ciesek, S. Lunemann, J. Jaroszewicz, and J. Wiegand Interferon alpha-Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1 J Infect Dis 205 9 2012 May 1 1351 1362
33. S.I. Khakoo, C.L. Thio, M.P. Martin, C.R. Brooks, X.J. Gao, and J. Astemborski HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection Science 305 5685 2004 Aug 6 872 874
34. D. Ge, J. Fellay, A. Thompson, J. Simon, K. Shianna, and T. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 7262 2009 Sep 17 399 401
35. D. Thomas, C. Thio, M. Martin, Y. Qi, D. Ge, and C. O'Huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 7265 2009 Oct 8 798 801
36. H. Tillmann, A. Thompson, K. Patel, M. Wiese, H. Tenckhoff, and H. Nischalke A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice Gastroenterology 139 5 2010 Nov 1586 1592 92.e1
37. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, and T. Mueller Genetic variation in il28b is associated with chronic hepatitis c and treatment failure: a genome-wide association study Gastroenterology 138 4 2010 1338 1345
38. S. Deuffic-Burban, H. Castel, J. Wiegand, M.P. Manns, H. Wedemeyer, and P. Mathurin Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: A model-based analysis J Hepatol 57 2 2012 Aug 260 266
39. P. Cacoub, T. Poynard, P. Ghillani, F. Charlotte, M. Olivi, and J. Piette Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group Multidepartment Virus C. Arthritis Rheum 42 10 1999 Oct 2204 2212
40. A. Zignego, C. Ferri, S. Pileri, P. Caini, and F. Bianchi Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach Dig Liver Dis 39 1 2007 Jan 2 17
41. D. Sene, N. Limal, and P. Cacoub Hepatitis C virus-associated extrahepatic manifestations: a review Metab Brain Dis 19 3-4 2004 Dec 357 381
42. S. Pischke, M. Cornberg, and M. Manns [Hepatitis associated cryoglobulinemia] Internist (Berl) 49 3 2008 Mar 297 304
43. C. Ferri, A. Zignego, and S. Pileri Cryoglobulins J Clin Pathol 55 1 2002 Jan 4 13
44. M. Vigano, P. Lampertico, M. Rumi, C. Folli, L. Maggioni, and A. Morabito Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients Gastroenterology 133 3 2007 Sep 835 842
45. C. Ferri, M. Sebastiani, D. Giuggioli, M. Cazzato, G. Longombardo, and A. Antonelli Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients Semin Arthritis Rheum 33 6 2004 Jun 355 374
46. D. White, V. Ratziu, and H. El-Serag Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis J Hepatol 49 5 2008 Nov 831 844
47. Y. Shintani, H. Fujie, H. Miyoshi, T. Tsutsumi, K. Tsukamoto, and S. Kimura Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 126 3 2004 Mar 840 848
48. R. Simó, A. Lecube, J. Genescà, J.I. Esteban, and C. Hernández Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection Diabetes Care 29 11 2006 2462 2466
49. B.J. Veldt, W.D. Chen, E.J. Heathcote, H. Wedemeyer, J. Reichen, and W.P. Hofmann Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus Hepatology 47 6 2008 Jun 1856 1862
50. V. Pattullo, and J. Heathcote Hepatitis C and diabetes: one treatment for two diseases? Liver Int 30 3 2010 Mar 356 364
51. N. Ishizaka, Y. Ishizaka, E. Takahashi, E. Tooda, H. Hashimoto, and R. Nagai Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening Lancet: England 359 9301 2002 Jan 133 135
52. A. Mostafa, M. Mohamed, M. Saeed, A. Hasan, A. Fontanet, and I. Godsland Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors Gut 59 8 2010 Aug 1135 1140
53. K. Weissenborn, J. Krause, M. Bokemeyer, H. Hecker, A. Schuler, and J. Ennen Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy J Hepatol 41 5 2004 Nov 845 851
54. M. Bokemeyer, X.Q. Ding, A. Goldbecker, P. Raab, M. Heeren, and D. Arvanitis Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy Gut 60 3 2011 Mar 370 377
55. M. Wiese, K. Grungreiff, W. Guthoff, M. Lafrenz, U. Oesen, and H. Porst Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study J Hepatol 43 4 2005 Oct 590 598
56. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 9055 1997 Mar 22 825 832
57. H. Thein, Q. Yi, G. Dore, and M. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and metaregression Hepatology 48 2 2008 Aug 418 431
58. J. Perz, G. Armstrong, L. Farrington, Y. Hutin, and B. Bell The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 4 2006 Oct 529 538
59. C. Sarrazin, C. Hezode, S. Zeuzem, and J.M. Pawlotsky Antiviral strategies in hepatitis C virus infection Journal of Hepatology 56 2012 Jan S88 100
60. A. Lok, D. Gardiner, E. Lawitz, C. Martorell, G. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 3 2012 Jan 19 216 224
61. T. Poynard, P. Mathurin, C.L. Lai, D. Guyader, R. Poupon, and M.H. Tainturier A comparison of fibrosis progression in chronic liver diseases J Hepatol 38 3 2003 257 265
62. S. Ryder, W. Irving, D. Jones, K. Neal, and J. Underwood Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Gut 53 3 2004 Mar 451 455
63. N. Svirtlih, D. Jevtovic, J. Simonovic, D. Delic, L. Dokic, and E. Gvozdenovic Older age at the time of liver biopsy is the important risk factor for advanced fibrosis in patients with chronic hepatitis C Hepatogastroenterology 54 80 2007 Dec 2324 2327
64. J. Zarski, J. Mc Hutchison, J. Bronowicki, N. Sturm, R. Garcia-Kennedy, and E. Hodaj Rate of natural disease progression in patients with chronic hepatitis C J Hepatol 38 3 2003 Mar 307 314
65. P. Pradat, N. Voirin, H. Tillmann, M. Chevallier, and C. Trepo Progression to cirrhosis in hepatitis C patients: an age-dependent process Liver Int 27 3 2007 Apr 335 339
66. S. Hissar, M. Kumar, P. Tyagi, A. Goyal, P. Suneetha, and S. Agarwal Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India J Gastroenterol Hepatol 24 4 2009 Apr 581 587
67. M. Yasuda, I. Shimizu, M. Shiba, and S. Ito Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats Hepatology 29 3 1999 Mar 719 727
68. R.K. Sterling, R.T. Stravitz, V.A. Luketic, A.J. Sanyal, M.J. Contos, and A.S. Mills A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans Clinical Gastroenterology and Hepatology 2 6 2004 469 473
69. T.E. Wiley, J. Brown, and J. Chan Hepatitis C infection in African Americans: its natural history and histological progression The American journal of gastroenterology 97 3 2002 700 706
70. H. Tillmann, D. Chen, C. Trautwein, V. Kliem, A. Grundey, and A. Berning-Haag Low frequency of HLA-DRB1* 11 in hepatitis C virus induced end stage liver disease Gut 48 5 2001 714 718
71. M. Thursz, R. Yallop, R. Goldin, C. Trepo, H.C. Thomas, and H. Grp Influence of MHC class II genotype on outcome of infection with hepatitis C virus Lancet 354 9196 1999 Dec 18 2119 2124
72. H. Huang, M.L. Shiffman, R.C. Cheung, T.J. Layden, S. Friedman, and O.T. Abar Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C Gastroenterology 130 6 2006 May 1679 1687
73. M. Marcolongo, B. Young, F. Dal Pero, G. Fattovich, L. Peraro, and M. Guido A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C Hepatology 50 4 2009 Oct 1038 1044
74. E. Trepo, P. Pradat, A. Potthoff, T. Gustot, A. Lemmers, and E. Quertinmont Impact of pnpla3 (Rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Journal of Hepatology 54 2011 Mar S55-S
75. C. Hui, T. Belaye, K. Montegrande, and T. Wright A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase J Hepatol 38 4 2003 Apr 511 517
76. P. Mathurin, J. Moussalli, J. Cadranel, V. Thibault, F. Charlotte, and P. Dumouchel Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity Hepatology 27 3 1998 Mar 868 872
77. C. Puoti, R. Guarisco, L. Spilabotti, L. Bellis, O. Mitidieri Costanza, and O. Dell' Unto Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma J Viral Hepat 19 4 2012 Apr 229 235
78. P.Y. Bochud, T. Cai, K. Overbeck, M. Bochud, J.F. Dufour, and B. Müllhaupt Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of hepatology 51 4 2009 655 666
79. A. Probst, T. Dang, M. Bochud, M. Egger, F. Negro, and P. Bochud Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and metaanalysis J Viral Hepat 18 11 2011 Nov 745 759
80. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9 6 2011 Jun 509 556
81. M.G. Rumi, F. De Filippi, C. La Vecchia, M.F. Donato, S. Gallus, and E. Del Ninno Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients Gut 54 3 2005 Mar 402 406
82. L. Fanning, E. Kenny, M. Sheehan, B. Cannon, M. Whelton, and J. O'Connell Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population Hepatology 29 3 1999 904 907
83. S. Maylin, C. Laouenan, M. Martinot-Peignoux, X. Panhard, M. Lapalus, and M.H. Nicolas- Chanoine Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy J Clin Virol 53 1 2012 Jan 43 47
84. E.M. Brunt, B.A. Neuschwander-Tetri, D. Oliver, K.R. Wehmeier, and B.R. Bacon Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens Human pathology 35 9 2004 1070 1082
85. K. Moriya, H. Yotsuyanagi, Y. Shintani, H. Fujie, K. Ishibashi, and Y. Matsuura Hepatitis C virus core protein induces hepatic steatosis in transgenic mice J General Virol 78 7 1997 1527 1531
86. E. Bugianesi, F. Salamone, and F. Negro The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 56 1 2012 S56 S65
87. N. Freedman, J. Everhart, K. Lindsay, M. Ghany, T. Curto, and M. Shiffman Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C Hepatology 50 5 2009 Nov 1360 1369
88. N. Freedman, T. Curto, K. Lindsay, E. Wright, R. Sinha, and J. Everhart Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C Gastroenterology 140 7 2011 Jun 1961 1969
89. S. Altekruse, K. McGlynn, and M. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 9 2009 Mar 20 1485 1491
90. H. El-Serag, J. Davila, N. Petersen, and K. McGlynn The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update Ann Intern Med 139 10 2003 Nov 18 817 823
91. Y. Tanaka, F. Kurbanov, S. Mano, E. Orito, V. Vargas, and J. Esteban Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality Gastroenterology 130 3 2006 Mar 703 714
92. C. Bosetti, F. Levi, P. Boffetta, F. Lucchini, E. Negri, and C. La Vecchia Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004 Hepatology 48 1 2008 Jul 137 145
93. A. Lok, L. Seeff, T. Morgan, A. di Bisceglie, R. Sterling, and T. Curto Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease Gastroenterology 136 1 2009 Jan 138 148
94. A. Sangiovanni, G. Prati, P. Fasani, G. Ronchi, R. Romeo, and M. Manini The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients Hepatology 43 6 2006 Jun 1303 1310
95. G. Fattovich, G. Giustina, F. Degos, G. Diodati, F. Tremolada, and F. Nevens Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) J Hepatol 27 1 1997 Jul 201 205
96. G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 5 Suppl. 1 2004 Nov S35 S50
97. L. Benvegnu, M. Gios, S. Boccato, and A. Alberti Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications Gut 53 5 2004 May 744 749
98. F. Degos, C. Christidis, N. Ganne-Carrie, J. Farmachidi, C. Degott, and C. Guettier Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death Gut 47 1 2000 131 136
99. S. Lai, P. Chen, K. Liao, C. Muo, C. Lin, and F. Sung Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study Am J Gastroenterol 107 1 2012 Jan 46 52
100. M.M. Hassan, L.Y. Hwang, C.J. Hatten, M. Swaim, D. Li, and J.L. Abbruzzese Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus Hepatology 36 5 2002 1206 1213
101. A. Potthoff, M.P. Manns, and H. Wedemeyer Treatment of HBV/HCV coinfection Expert Opin Pharmacother 11 6 2010 Apr 919 928
102. V. Kumar, N. Kato, Y. Urabe, A. Takahashi, R. Muroyama, and N. Hosono Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma Nature genetics 43 5 2011 455 458
103. L.H. Omland, H. Krarup, P. Jepsen, J. Georgsen, L.H. Harritshoj, and K. Riisom Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study J Hepatol 53 1 2010 Jul 36 42
104. H.F. Gidding, J. Amin, G.J. Dore, K. Ward, and M.G. Law Hospital-related morbidity in people notified with hepatitis C: a population-based record linkage study in New South Wales, Australia J Hepatol 53 1 2010 Jul 43 49
105. R. Planas, B. Ballesté, M. Antonio Álvarez, M. Rivera, S. Montoliu, and J. Anton Galeras Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients J Hepatol 40 5 2004 823 830
106. A. Di Bisceglie, M. Shiffman, G. Everson, K. Lindsay, J. Everhart, and E. Wright Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 23 2008 Dec 4 2429 2441
107. J. Bruix, T. Poynard, M. Colombo, E. Schiff, K. Burak, and E.J. Heathcote Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C Gastroenterology 140 7 2011 Jun 1990 1999
108. M. Tong, N. el-Farra, A. Reikes, and R. Co Clinical outcomes after transfusion associated hepatitis C N Engl J Med 332 22 1995 Jun 1 1463 1466
109. V. de Ledinghen, P. Trimoulet, P. Mannant, F. Dumas, P. Champbenoit, and C. Baldit Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins:long-term follow-up of 196 patients (4535 patient-years) J Hepatol 46 1 2007 Jan 19 25
110. M. Wiese, F. Berr, M. Lafrenz, H. Porst, and U. Oesen Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicentre study Hepatology 32 1 2000 Jul 91 96
111. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 16 1999 Apr 22 1228 1233